This finding also implies considerations for the clinical management of high-risk patients with unfavorable prognoses: For clinically initially treated high-risk B-ALL patients at great risk of relapse and patients who are willing to intervene early with CAR-T cell therapy, it is important to take into account the need for later CAR-T cell therapy or Blinatumomab to minimize the use of cytotoxic drugs such as Zoerythromycin, Prednisolone, or Vincristine and to shorten the duration of bridging therapy to avoid the downregulation of CD58 in order to ensure the efficacy. This evidence concerns the gene CD58 and acute lymphoblastic leukemia.